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Background: Rapid diagnostic test (RDT) is becoming an alternative way of establishing quickly the diagnosis of
malaria infections, by detecting specific malaria antigens in suspected patients’ blood between the China-Myanmar
endemic borders areas, towards achieving the National Malaria Elimination programme by 2020. The objective of
this study is to evaluate the performance of CareStart™ Malaria Pf/Pan RDT kit for the diagnosis of malaria infections
in suspected patients. Blood examination by microscopy was taken as gold standard to evaluate CareStart™ kit’s
sensitivity, specificity and predictive value and corrected with PCR assay.
Results: Overall 126 of 241 (52.28%) malaria cases were detected by microscopy compared to 115 of 241(47.72%)
CareStart™ kit and 128 of 241 (53.11%) PCR corrected assay. CareStart™ kit’s sensitivity and specificity for the
diagnosis of malaria were 89.68% and 98.26% respectively, compared to standard microscopy, whereas the
sensitivity and specificity for falciparum malaria were 88.52% and 98.26%, and for vivax malaria: 90.77% and 100%.
The CareStart™ positive predictive values were 98.26% (93.88-99.52%, 95% CI) compared to 100% (96.77-100%,
95% CI) for PCR-corrected, and the negative predictive values of 89.68% (83.15-93.87%, 95% CI) were the same in
microscopy as PCR-corrected. The diagnostic accuracy of CareStart™ kit versus microscopy and PCR were 93.78%
(89.99-96.19%, 95% CI) and 94.61% (90.99-96.82%, 95% CI) respectively. The likelihood of diagnostic of malaria
positive was almost similar between microscopy and CareStart™ kit, with an entropy reduction of 60.0% compared
to a weak likelihood of misdiagnosis of 0.10 (0.09-0.12, 95% CI), with an entropy reduction of 36.01%.
Conclusion: The accuracy of CareStart™ kit is comparable to gold standard microscopy in these areas, it is easy to
perform and suitable for cross-border diagnosis and monitoring of local or imported malaria patterns by any local
health staff in endemic remotes.
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Malaria remains unevenly endemic across Yunnan The
CareStart™ P.f/P.v Combo province, Southeast China.
Within Yunnan, malaria occurs mainly at the border
areas, in the drainage areas of the Yuanjiang River and
amongst the high population of motile ethnic minority* Correspondence: tambo0711@gmail.com
2National Institute of Parasitic Diseases, Chinese Center for Diseases Control
and Prevention, WHO Collaborating Center on Malaria, Schisostomiasis and
Filariasis, Shanghai 200025, China
Full list of author information is available at the end of the article
© 2013 Xiaodong et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orgroups at risk living in forests and on forest fringes for
economic reasons, on the China-Myanmar borders [1].
While parasite-based diagnosis is increasing, most sus-
pected cases of malaria are not properly identified, with
accurate diagnosis and disease monitoring consequently
remaining elusive [2].
Although malaria cases and deaths have dropped subs-
tantially over the past decade, efforts must be intensified
in the malaria-endemic communities to abolish the pub-
lic threat of malaria by prompt diagnosis and effectiveral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trials and the heterogeneous nature of malaria transmis-
sion has limited the availability of good quality perform-
ance diagnostic that the National Malaria Elimination
programme requires for a surveillance response system
and to make informed decisions and implementation to-
wards malaria elimination by 2020.
Technical support for malaria prevention and control
in China is provided at national level by the National In-
stitute of Parasitic Diseases, Chinese Center for Disease
Control and Prevention (CDC), based in Shanghai. The
strategies of the National Malaria Elimination program-
me 2010–2020 include greater access to early diagnosis
and prompt treatment coverage in remote areas, free
distribution of long-lasting, insecticide-treated bed nets
(LLINs), strengthening quality and regulatory mechanisms
for anti-malarial drugs, strengthening malaria surveillance
and information systems, epidemic preparedness, increa-
sing the awareness of malaria, involvement and empower-
ment, basic and applied research on Plasmodium vivax
and Plasmodium falciparum, whilst monitoring the in-
dicators for malaria elimination [3]. Moreover, World
Health Organization (WHO) recommends that malaria
case management be based on parasite-based diagnosis in
all cases, with the exception of young children in areas of
high transmission and where lack of resources or need for
urgent response temporarily limits its applications [1-4]
The use of antigen-detecting rapid diagnostic tests (RDTs)
forms a vital part of this strategy, providing the possibility
of parasite-based diagnosis in areas where good quality
microscopy cannot be maintained [4]. There are numer-
ous malaria RDTs that are commercially available in many
formats, including plastic cassettes, cards or dipsticks, and
quality depends on manufacturer as well as storage condi-
tions [5]. The variation depends on malaria antigen tar-
geted for detection in blood flowing along a membrane
containing specific anti-malaria antibodies. Previous stu-
dies from clinical trials have found that HRP-2 based P.
falciparum-specific tests generally have greater sensitivity
(over 90%) than the pLDH-based tests when compared
with microscopy in clinical cases, whilst sensitivity of
pLDH tests for non-P. falciparum species was low [6,7].
Specificity of both types of tests was reported to be good
(>85%). Despite the encouraging results from the RDT
trials in clinical cases, there is limited information about
the sensitivity, specificity and predictive value in the en-
demic China-Myanmar malaria population where labora-
tory facilities are not available. Reports of wide variation
in accuracy of malaria RDTs in published field trials usu-
ally compared with light microscopy as a gold standard
[8-10]. The CareStart™ P.f/P.v combo test (detecting
histidine-rich protein (pHRP-2) and P. vivax-specific
lactate dehydrogenase (pLDH) has been evaluated in
a few field settings, including higher sensitivities forP. falciparum (99.4%) reported in Ethiopia with P. fal-
ciparum samples with parasite densities above 100/μl,
[11], sensitivities for P. falciparum low values at para-
site densities <100/μl (60.0%) and increasing sensitivity at
higher parasite densities (100% at >500/μl) reported in
Madagascar [12], and sensitivities for the detection of P.
vivax were significantly higher than those found in Ethi-
opia with pLDH (pan) (91.0%), but similar results for the
CareStart™ malaria pLDH (pan/Pf) reported in Myanmar
[13]. Similarly, some studies evaluating other RDTs in
non-endemic countries reported similar sensitivities as
those found for the CareStart™ malaria HRP-2/pLDH (Pf/
pan) combo test but a different degree of sensitivity and
specificity for P. falciparum ranging from 87.5-99.0%
[6-14] and for P. vivax, RDTs detecting pan-pLDH sho-
wed sensitivities ranging from 62.0-95.0%, [10-15] com-
pared to 46.0%-93.0% for those RDTs targeting aldolase
[16]. The increase of sensitivities at higher parasite
densities is a well known phenomenon with breakpoints
around 100/μl (P. falciparum) and 500/μl (P. vivax)
[6,13,17,18].
The aim of the study was to evaluate the performance
of CareStart™ malaria Pf/pan test kit in early diagnosis
for prompt effective case management of malaria.
Methods
Study design
The CareStart™ malaria HRP-2/pLDH (Pf/pan) combo test
was evaluated in suspected patients attending TengChong
CDC, China and Health Unlimited clinic in Laiza City,
Kachin State, Myanmar, near the China-Myanmar border.
Standard microscopy method was done for all thick smears
corrected by polymerase chain reaction (PCR) assay. The
assessment of the diagnostic performance was performed
in comparison the CareStart™ (CS) kit with gold standard
microscopic results, corrected by PCR assay.
Blood sample collection
The study was conducted in July to December, 2011 in
TengChong CDC, China and Health Unlimited clinic in
Laiza City, Kachin State, Myanmar, near the China-
Myanmar border on all suspected patients. Individual
biodata and malaria history in the previous one year
were documented from each suspected case as well as
an informed consent. All patients had venous blood sam-
ples collection for microscopy and CS kit evaluation and
also samples were collected in EDTA and stored at −20°C
condition for PCR analysis.
Ethical clearance
The study was reviewed and approved by the Ethical
Committee of Yunnan Institute of Parasitic Diseases,
Yunnan province and Health Ministry of Kachin State of
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admission into the study.
Standard microscopy evaluation
Duplicate thin and thick slides were made from all blood,
stained using 5% Giemsa stain and dyed for 30 minutes,
read under x100 electron microscopy. The malaria micro-
scopic examination was performed by two independent
experienced microscopists, for identification of the mal-
aria parasite species. The number of parasites was counted
against 200 leucocytes and quantification of parasite dens-
ity was estimated by assuming 8,000 leucocytes/μl blood.
Samples were considered negative when no parasite was
detected after examining 100 microscopic fields [19]. In
order to check for interobserver difference, a double-blind
cross reading of a random 50 blood slides was performed
by a senior microscopist.
CareStart™ malaria kit assessment
The CS RDT kit contains a membrane strip, which is
pre-coated with two monoclonal antibodies as two sep-
arate lines across a test strip. One monoclonal antibody
(test line 2) is pan-specific to lactate dehydrogenase
(pLDH) of the Plasmodium species (P. falciparum, P.
vivax, Plasmodium malariae and Plasmodium ovale)
and the other line (test line 1) consists of a monoclonal
antibody specific to histidine-rich protein 2 (HRP2) of the
P. falciparum species. The conjugate pad is dispensed with
monoclonal antibodies, which are pan-specific to pLDH
and P. falciparum specific to HRP2. The CS RDT kit is
designed for the differential diagnosis between P. falcip-
arum and other pan-specific species. The CS RDT kit was
supplied by the China-England Advanced Communication
Project and is produced by American Access Bio Com-
pany; batch number C201R, period of validity to February
2012. The test reproducibility was evaluated by testing 15
samples representing all species at variable parasite dens-
ities on three consecutive occasions in Teng Chong CDC.
CareStart™ malaria test procedures
Tests were performed according to manufacturer’s ins-
tructions. Readings were carried out at daylight, assisted
by a standard electric bulb, by three health worker-obser-
vers performing and interpreting the test results. The first
observer performed readings at 20 minutes, reading time
recommended by the manufacturer, followed by observers
2 and 3 within the next 10 minutes. The observers were
blinded to each other’s readings and to the results of mi-
croscopy and PCR assay.
In the case when no control line appeared, the test
was considered invalid and was repeated. To score line
intensities, a scoring system of five categories was used
as defined previously [7]: none (no line visible), faint
(barely visible line), weak (paler than the control line),medium (equal to the control line) or strong (stronger
than the control line).
The test results were based on consensus agreement,
which meant that an identical result read by at least two
out of three health worker-observers was withheld. In
the case of no consensus, the results of the first reader
were considered. To assess inter-observer agreement,
results of positive and negative readings as well as line
intensities were considered.
Test detection and validation
The sensitivity and specification of CS RDT kit were
performed by random selection of P. falciparum and P.
vivax cases, and negative blood samples for 10 times re-
peat tests, and the results estimated following the manu-
facturer specification.
Plasmodium species identification
All cases were identified by microscopy and analysed by
real-time PCR for detection of the 18 s rRNA of malaria
parasite for confirmation, species identification and de-
termination of parasite density, as described previously
[20]. In the case of discordant results between micros-
copy and PCR, the results of PCR were used as the
standard method.
Data analysis
All data were processed using Excel to build database
and Wilson score software was used for analysis. Sensi-
tivity, specificity and predictive values were calculated
separately for P. falciparum and the non-falciparum spe-
cies with 95% CI.
The Pearson Chi-square test was used to determine
significance of results, or in the case of a small sample
size, a two-tailed Fisher’s exact test. A p-value <0.05 was
considered statistically significant.
Results
General characteristics of patients
A total of 241 blood samples from suspected patients
were analysed for malaria parasites by the CS RDT kit
and the results were compared with results from gold
standard microscopy, corrected by PCR assay. The male:
female ratio was 3.54:1. The mean age was 29.62 ±
11.21 years (range 3–58 years old) of which the majority
89.21% (215) were older than 18 years and only four
patients (1.66%) were under five years. The microscopic
results indicated that 52.28% (126 of 241) of patients
were infected with malaria. Among the malaria-positive
patients, 51.58% (65 of 126) harboured P. vivax, 43.63%
(55 of 126) had P. falciparum, and 4.76% (six of 126)
mixed infections of P. vivax and P. falciparum. There
were only two cases of missed diagnosis observed by
microscopy.
Table 1 General characteristics of patients
Total 241
Mean age (range) (years) 29.62 ± 11.21 (3–58)
Age group (%) ≤5 years old 4 (1.66%)
5–18 years old 22 (9.13%)
>18 years old 215 (89.21%)
Gender (%) Male 188 (78.01%)
Female 53 (21.99%)
Geometric mean parasite density (range)/μl 5,990 (48~377143)/μl
Parasite density distribution <100/μl 4 (3.18)%
100 ~ 1,000/μl 15 (11.90%)
>1,000/μl 107 (84.92%)
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(48~377143/μl. The parasite density distribution showed
that 3.18% cases were <100 parasites/μl, 11.90% cases were
between 100~1000/μl and 84.95% cases were >1,000
parasites/μl.
The median parasite density in 13 missed cases by CS
was 348/μl, ranged from 48 ~ 22,688/μl, of which four
cases were <100 μl, three cases between 100~1,000/μl and
six cases were >1,000 parasites/μl (see Table 1).
Comparison of CareStart™ kit, standard microscopy and
polymerase chain reaction results
Two (1.58%) positive cases initially misdiagnosed by mi-
croscopy were identified by PCR assays and CS RDT kit.
There was no significant difference between the sensi-
tivity of PCR and standard microscopy, however the
specificity of PCR assay was 100% against 98.26% for mi-
croscopy. The diagnostic accuracies of both diagnostic
methods were comparable. The likelihood of ratio of aTable 2 Comparison with microscopy and polymerase chain r




Sensitivity (95% IC)% 89.68 (83.15, 93.87
Specificity (95% IC)% 98.26 (93.88, 99.52
Positive Predictive Value (95% IC)% 98.26 (93.88, 99.52
Negative Predictive Value (95% IC)% 89.68 (83.15, 93.87
Diagnostic Accuracy 93.78 (89.99, 96.19
Likelihood ratio of a Positive Test 51.57 (19.32 – 137
Likelihood ratio of a Negative Test 0.11 (0.09, 0.12)
Diagnostic Odds 491.1 (108.3 – 222
Cohen’s kappa (Unweighted) 0.88 (0.75 – 1.00)
Entropy reduction after a Positive Test% 60.44
Entropy reduction after a Negative Test% 36.01
Bias Index −0.04positive test and negative test were 51.57 (19.32-137.7)
and 0.11 (0.09, 0.12) respectively. The negative entropy
after a positive microscopic test was 60.44%, whereas the
microscopy and PCR entropy reduction after a negative
test were 36.1% and 35.96% respectively. There was no
significant difference between the Cohen’s kappa values
of microscopy compared to PCR assay (see Table 2).CareStart™ malaria test results
The CS kit results indicated that 47.72% (115/241) of
the patients were infected with malaria. Among the posi-
tive samples, malaria species identified showed that P.
vivax represented 51.30% (59/115), P. falciparum or
P. falciparum mixed other species was present 48.70%
(56/115). Two cases microscopically negative were CS
kit P. falciparum positive whereas 13 cases (six cases of
P. vivax and seven cases of P. falciparum) originally
detected by microscopy were not detected by CS RDT
kit. The summary results of microscopy and CS kit
results are showed in Table 3.Sensitivity, specificity and predictive values of CareStart™
malaria kit
The CareStart™ P.f/P.v Combo test sensitivity ranged bet-
ween 88.55 - 90.77% and specificity ranged 98.26 - 100%
(95%CI) when compared to gold standard microscopic
blood films for detection of malaria. The mean CS malaria
P.v/P.f rapid kit sensitivity was 89.68% (83.15-93.97%,
95% CI) and mean specificity was 98.26% (93.88-100%,
95% CI). The positive predictive value was 98.26% (93.88-
99.52, 95% CI) and negative predictive value of 89.68%
(89.68-3.87%, 95% CI) when compared to traditional blood





) 89.84 (83.4, 93.97 )
) 100 (96.71, 100 )
) 100 (96.77, 100 )
) 89.68 (83.15, 93.87 )








Table 3 CareStart™ and PCR sensitivity, specificity and predictive values
CS Diagnostic Kit Microscopy PCR
P. falciparum* P. vivax P. falciparum* P. vivax
Positive Negative Positive Negative Positive Negative Positive Negative
Positive 54 2 59 0 56 0 59 0
Negative 7 113 6 115 7 113 6 113
Sensitivity (95% IC)% 88.52 (78.16, 94.33) 90.77 (81.29, 95.7) 88.89 (78.8, 94.51) 90.77 (81.29, 95.7)
Specificity (95% IC)% 98.26 (93.88, 99.52) 100 (96.77, 100) 100 (96.71, 100) 100 (96.71, 100)
Positive Predictive Value (95% IC)% 96.43 (87.88, 99.02) 100 (93.89, 100) 100 (93.58, 100) 100 (93.89, 100)
Negative Predictive Value (95% IC)% 94.17 (88.45, 97.15) 95.04 (89.6, 97.71) 94.17 (88.45, 97.15) 94.96 (89.44, 97.67)
Diagnostic Accuracy (95% IC)% 94.89 (90.57, 97.29) 96.67 (92.92, 98.46) 96.02 (92.02, 98.06) 96.63 (92.84, 98.45)
Cohen’s kappa (Unweighted) 0.89 (0.74, 1.03) 0.93 (0.78,1.07) 0.91 (0.76, 1.06) 0.93 (0.78, 1.07)
*Plasmodium falciparum.
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93.78% (89.99-96.19%) (see Table 3).
Results of polymerase chain reaction assay
Real-time PCR for diagnosis of malaria, and identifica-
tion of parasite species showed a difference in P. falcip-
arum and P. vivax sensitivity of 88.89% and 90.77%, but
similar specificity species identification of 100%. The
assay confirmed 128 Plasmodium cases of which 49.22%
(63/128) were falciparum against the predominant 50.72%
(65/128) vivax malaria in the areas. In contrast, CS diag-
nosis had a lower specificity to P. vivax of 98.26%, but
same specificity for P. falciparum when compared with
corrected PCR assay results, as shown in Table 3.
Discussion
The important finding of this study was that the CS kit
had sensitivity of 89.68% and specificity of 98.26% com-
pared to the gold standard microscopy method for de-
tection of malaria. The CS sensitivity for the detection of
P. falciparum was 98.3% and 99.3% in samples with
parasite densities above 100/μl and 1,000/μl respectively
whereas the sensitivity for P. vivax was 97.6% for para-
site densities above 500/μl. No positive result occurred
among the Plasmodium-negative samples, which is con-
sistent with the recent study of CS kit in Ethiopia [21].
RDTs detecting P. vivax-specific pLDH CS kit based on
specific monoclonal antibody, detected histidine-rich
protein 2(HRP-2, test line 1) and four kinds of lactic acid
dehydrogenase of Plasmodium in human blood (pLDH,
test line 2) in a card detection device, aseptic and single
packing. The comparison of the sensitivity and specifi-
city of the CS-RDTs versus microscopy corrected by
PCR assay (Table 3) indicated that the detection rate
was relatively similar for P. vivax and P. falciparum, in-
dicating that the microscopic training performed had a
high efficiency on the performance microscopists. This
kit showed no need of sophisticated equipment and fa-
cilities, and was easy to operate. Its applicability andrapidity in diagnosis could be of additional value for
both falciparum and vivax malaria detection and prompt
case management as well as cross borders malaria moni-
toring in the China-Myanmar endemic areas in the Na-
tional Malaria Elimination programme.
In total, 241 kits, and 20 kits for quality assurance
and control, were used in this study without the invalid
case, specificity and sensitivity of this batch kit was
100%, which implied the quality was stable. However,
the false negative rate of (10.4%) 13/126 documented in
the study can be explained only partly by the CS
threshold level of >100 parasites/μl and probably the
CS storage conditions and duration in the field resulted
in loss of sensitivity, since the quality assurance and
control testing was 100%.
As shown in Tables 2 and 3, the diagnostic standards
of kit were highly specific and sensitive, indicating that
kit was valuable for malaria diagnosis.
The CareStart™ P.f/P.v Combo (detecting HRP-2 and
P. vivax-specific pLDH) test has been evaluated in Ethi-
opia [11-25] compared to this study which reported
higher sensitivity for P. falciparum (99.4%). No clear rea-
son could be given for increasing sensitivity and possibly
included exclusively P. falciparum samples with parasite
densities above 100/μl, which is above the detection
threshold of most RDTs [22]. Also, CareStart™ malaria
pLDH (Pf/pan) combo test has been evaluated in a field
study in Madagascar which reported sensitivities for P. fal-
ciparum low values at parasite densities <100/μl (60.0%)
and increasing sensitivity at higher parasite densities
(100% at >500/μl) [23].
The two products (CareStart™ malaria pLDH (Pf/pan)
combo test) and CareStart™ brand (malaria pLDH (pan)),
evaluated in Myanmar, reported sensitivities for the detec-
tion of P. vivax were significantly higher than those found
in Ethiopia with pLDH (pan) (91.0%), but results were
similar for the CareStart™ malaria pLDH (pan/Pf) [13-25].
A study in The Philippines compared the results of the
ICT malaria P.f/P.v RDT with microscopy and found a
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arum by the RDT, but negative by microscopy [24].
The CareStart™ malaria pLDH (Pf/pan) combo test field
study in Madagascar reported sensitivities for P. falcip-
arum that are comparable to the present study, but there
were only nine P. vivax samples included, making com-
parison difficult [12]. Moreover, the CareStart™ brand
(malaria pLDH (pan)) has also been evaluated in Myanmar
with similar results obtained across the China-Myanmar
malaria endemic borders [13].
When PCR was the reference method, the microscopic
method showed a low specificity (88.2%). The P. vivax
and P. falciparum positive and negative predictive values
of CS were 100% and 94.96% compared to 100% and
94.17% respectively. In addition, P. vivax diagnostic ac-
curacy of CS was 96.67% compared to 94.89% for P. fal-
ciparum. The differential explanation could be the lack
of differentiation of other species of Plasmodium species
as reported in Thailand [6]. However, the two blood
slides from the samples could not show malaria parasites
microscopically. The negative predictive values of CS
observed could not be directly explained but may be
attributed to possible genetic heterogeneity of HRP2 as
well as possible geographic variations in malaria antigens.
This study recorded two misdiagnosed microscopic
cases, corrected using PCR assay, whereas 13 cases were
not detected by CS kit. The reported sensitivities for the
detection of P. vivax were significantly higher than those
found in the present study in case of the CareStart™
malaria pLDH (Pf/pan) (88.52%), but for the CareStart™
malaria pLDH (Pv/pan) they were in line with the previ-
ous findings (90.77%) [10,11].
Studies evaluating other RDTs in non-endemic coun-
tries report similar sensitivities as those found for the
CareStart™ malaria HRP-2/pLDH (Pf/pan) combo test
in this study for P. falciparum where they ranged from
87.5-99.0%, with one exception of 76.2%, whereas for P.
vivax, RDTs detecting pan-pLDH showed sensitivities of
33.5% and 62.0%-95.0% [6-9]. The detection rates as
demonstrated by WHO/FIND are slightly higher as
compared to the sensitivities found in this study, but the
differences were not statistically significant [4].
The specificity and sensitivity of CS kit were 89.68%
and 98.26%, a difference not statistically significant than
previous CS results in southwest Ethiopia (see Table 2)
[11]. The sensitivity and specificity documented in this
study can be accounted for by the long historical trends
of anti-malarial usage, counterfeit, substandard and coun-
ter prescription contributing to the progression of select-
ive pressure of malaria parasites in the blood stream and
hence low parasitaemia below the CS kit detection thresh-
old. The findings showed that CS usefulness in detection
and case management of malaria in remote areas and on
motile populations across borders has implications in thesearch for more efficient and sensitive diagnostic tools for
parasite detection and case management in areas of low
endemicity, as well as targeting gametocyte detection to-
wards blocking the transmission, and monitoring malaria
elimination.
Conclusion
The study demonstrated that the CareStart™ malaria
HRP-2/pLDH (Pf/pan) combo test performs satisfactory
well for the detection of P. falciparum and P. vivax ma-
laria infections in cross-border malaria. Hence, providing
a rationale surveillance response system for malaria cross-
border control and elimination programmes in conjunc-
tion with national malaria programmes is urgently needed
for China’s National Malaria Elimination programme for
2020.
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